# Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes

> **NCT03563794** · PHASE4 · UNKNOWN · sponsor: **The First Affiliated Hospital of Xiamen University** · enrollment: 400 (estimated)

## Conditions studied

- T2DM

## Interventions

- **DRUG:** CSII+Vildagliptin
- **DRUG:** CSII(insulin Lispro)

## Key facts

- **NCT ID:** NCT03563794
- **Lead sponsor:** The First Affiliated Hospital of Xiamen University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-10
- **Primary completion:** 2019-06-10
- **Final completion:** 2019-12-10
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2018-06-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03563794

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03563794, "Efficacy and Safety of Vildagliptin Added to Continuous Subcutaneous Insulin Infusion in Uncontrolled Type 2 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03563794. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*